Gilead Buys Santa Monica's Kite Pharma in $12 Billion Cancer-Drug Deal

Gilead Buys Santa Monica's Kite Pharma in $12 Billion Cancer-Drug Deal

Gilead Buys Santa Monica's Kite Pharma in $12 Billion Cancer-Drug Deal

Kite's shares were up by 28.87% in pre-market trading on heavy volume as a result. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company's stock, valued at approximately $227,197,799. The company has market cap of $98.53 billion.

Shares of Kite Pharma (NASDAQ:KITE) traded down 0.06% on Tuesday, reaching $177.95.

About 10.50 million shares traded or 31.58% up from the average. Kite Pharma Inc (NASDAQ:KITE) has risen 55.47% since August 29, 2016 and is uptrending. It has underperformed by 0.05% the S&P500.

Leavell Investment Management Inc decreased Gilead Sciences Inc Com (GILD) stake by 23.58% reported in 2016Q4 SEC filing.

The company is up by 28.18% since yesterday's close of $139.1. The company had revenue of $10.10 million during the quarter, compared to the consensus estimate of $9.59 million.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. (NASDAQ:GILD) for 4,499 shares.

Medidata Solutions Inc.is a well-known provider of cloud solutions for life sciences. It has outperformed by 38.77% the S&P500. 5,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $325,114 were sold by Alton Gregg H.

Arsenal reject Man City's £50 million Alexis Sanchez offer
But Guardiola, who was in charge at Sanchez's former club FC Barcelona, is understood to want the Chilean as a straight purchase. But they may be willing to include Raheem Sterling to sweeten the deal for Arsenal .

And now he doesn't have to worry about the soaring stock price, which has added another 29 percent in the wake of the Gilead news. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: "Gilead - Investors, Start Your Engines" on August 01, 2017, also Seekingalpha.com with their article: "Gilead: Road To $100" published on August 18, 2017, Seekingalpha.com published: "Mavyret Could Amplify Gilead's HCV Pain" on August 14, 2017.

Investors sentiment decreased to 1.31 in Q4 2016. Its down 0.23, from 0.93 in 2016Q3.

EVP, Business Development, Kim Helen Susan, sold 79,949 common shares of Kite Pharma, Inc. 20 funds opened positions while 32 raised stakes. EOG shares are down 0.8% to $83.82 premarket. Eventide Asset Ltd Limited Liability Company has invested 0.37% in Kite Pharma Inc (NASDAQ:KITE). Susquehanna International Group, Llp grew its ownership by buying 73,176 shares an increase of 34.2% from 03/31/2017 to 06/30/2017. Blackrock Invest Mgmt Limited Liability Co reported 3,208 shares. Us Fincl Bank De invested in 0% or 6 shares. Moreover, Capital Guardian Trust has 0.16% invested in Kite Pharma Inc (NASDAQ:KITE) for 463,700 shares. Suntrust Banks reported 0.12% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) by 88.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. Credit Suisse Ag has invested 0% in Tristate Capital Holdings Inc (NASDAQ:TSC). Kcg Holdg Incorporated has invested 0.03% in Kite Pharma Inc (NASDAQ:KITE). (NASDAQ:GILD) for 12,448 shares.

On July 13 the company was changed to a "Hold" according to a Maxim Group report down from the previous "Buy" rating. Therefore 50% are positive. (The) raised their price objective on shares of Kite Pharma from $85.00 to $89.00 and gave the stock a buy rating in a report on Tuesday, May 9th. The stock of Gilead Sciences, Inc. As per Tuesday, June 27, the company rating was maintained by Canaccord Genuity. The rating was initiated by Leerink Swann with "Market Perform" on Tuesday, April 26. Creative Planning reported 0% in Kite Pharma Inc (NASDAQ:KITE). As per Thursday, June 8, the company rating was upgraded by BTIG Research.

Since May 24, 2017, it had 0 insider purchases, and 2 selling transactions for $1.02 million activity. It fall, as 3 investors sold Mattersight Corp shares while 5 reduced holdings. 125,600 are owned by Factory Mutual. Oz Ltd Partnership stated it has 51,900 shares. Shares for $1.17 million were bought by Belldegrun Arie.

"We still like the shares heading into the end of the year", said Schroer, whose firm holds about 118,000 shares, by phone. Point72 Asset Management L P holds 244,722 shares or 0.08% of its portfolio. "We will take some time to look at our own portfolio and see what else we can do". 16,210 are held by Duff & Phelps Inv Mngmt. Hilltop accumulated 2,889 shares. Sg Americas owns 32,413 shares. (NASDAQ:AMGN) or 1,467 shares. Tristate Cap Hldgs Inc now has $603.41 million valuation.

Related news